{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:19:30Z","timestamp":1788045570265,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s11892-008-0037-7","type":"journal-article","created":{"date-parts":[[2008,10,11]],"date-time":"2008-10-11T23:18:40Z","timestamp":1223767120000},"page":"214-220","source":"Crossref","is-referenced-by-count":23,"title":["Antihypertensive medications and their effects on lipid metabolism"],"prefix":"10.1007","volume":"8","author":[{"given":"Mrunalini","family":"Deshmukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy I.","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Whaley-Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,11]]},"reference":[{"key":"37_CR1","unstructured":"National Center for Health Statistics: Health, United States, 2007 (with a chart book on the health of Americans). Available at http:\/\/CDC.gov\/nchs\/hus.htm. Accessed February 27, 2008."},{"key":"37_CR2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560\u20132572.","journal-title":"JAMA"},{"key":"37_CR3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa003417","volume":"345","author":"R.S. Vasan","year":"2001","unstructured":"Vasan RS, Larson MG, Leip EP, et al.: Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291\u20131297.","journal-title":"N Engl J Med"},{"key":"37_CR4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.284.4.465","volume":"284","author":"H.M. Perry Jr","year":"2000","unstructured":"Perry HM Jr, Davis BR, Price TR, et al.: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000, 284:465\u2013471.","journal-title":"JAMA"},{"key":"37_CR5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.282.6.539","volume":"282","author":"J.A. Staessen","year":"1999","unstructured":"Staessen JA, Thijs L, Fagard R, et al.: Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999, 282:539\u2013546.","journal-title":"JAMA"},{"key":"37_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2796.2005.01497.x","volume":"257","author":"T. Almgren","year":"2005","unstructured":"Almgren T, Persson B, Wilhelmsen L, et al.: Stroke and coronary heart disease in treated hypertension: a prospective cohort study over three decades. J Intern Med 2005, 257:496\u2013502.","journal-title":"J Intern Med"},{"key":"37_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/bmj.317.7152.167","volume":"317","author":"O.K. Andersson","year":"1998","unstructured":"Andersson OK, Almgren T, Persson B, et al.: Survival in treated hypertension: follow up study after two decades. BMJ 1998, 317:167\u2013171.","journal-title":"BMJ"},{"key":"37_CR8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/01.ATV.10.2.223","volume":"10","author":"M. Laakso","year":"1990","unstructured":"Laakso M, Sarlund H, Mykkanen L: Insulin resistance with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990, 10:223\u2013231.","journal-title":"Arteriosclerosis"},{"key":"37_CR9","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1001\/archinte.159.18.2206","volume":"159","author":"D.M. Lloyd-Jones","year":"1999","unstructured":"Lloyd-Jones DM, Evans JC, Larson MG, et al.: Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med 1999, 159:2206\u20132212.","journal-title":"Arch Intern Med"},{"key":"37_CR10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.ATV.5.4.391","volume":"5","author":"S.W. MacMahon","year":"1985","unstructured":"MacMahon SW, Macdonald GJ, Blacket RB: Plasma lipoprotein levels in treated and untreated hypertensive men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study. Arteriosclerosis 1985, 5:391\u2013396.","journal-title":"Arteriosclerosis"},{"key":"37_CR11","first-page":"249","volume":"16","author":"F.B. Lepira","year":"2005","unstructured":"Lepira FB, M\u2019Buyamba-Kabangu JR, Kayembe KP, Nseka MN: Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension. Cardiovasc J S Afr 2005, 16:249\u2013255.","journal-title":"Cardiovasc J S Afr"},{"key":"37_CR12","first-page":"1457","volume":"17","author":"L. Lind","year":"1995","unstructured":"Lind L, Berne C, Lithell H: Prevalence of insulin resistance in essential hypertension. J Hypertens 1995, 17:1457\u20131462.","journal-title":"J Hypertens"},{"key":"37_CR13","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"G.M. Reaven","year":"1988","unstructured":"Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595\u20131607.","journal-title":"Diabetes"},{"key":"37_CR14","first-page":"713","volume":"86","author":"S.I. McFarlane","year":"2001","unstructured":"McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713\u2013718.","journal-title":"J Clin Endocrinol Metab"},{"key":"37_CR15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1254\/jphs.91.182","volume":"91","author":"K. Sakurai","year":"2003","unstructured":"Sakurai K, Sawamura T: Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 2003, 91:182\u2013186.","journal-title":"J Pharmacol Sci"},{"key":"37_CR16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0531-5131(03)01816-8","volume":"1262","author":"T. Sawamura","year":"2004","unstructured":"Sawamura T: LOX-1, a lectin-like oxidized LDL receptor identified from endothelial cells, in endothelial dysfunction. Int Congr Ser 2004, 1262:531\u2013534.","journal-title":"Int Congr Ser"},{"key":"37_CR17","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/ATVBAHA.107.152272","volume":"27","author":"A. Dandapat","year":"2007","unstructured":"Dandapat A, Hu C, Sun L, Mehta JL: Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler Thromb Vasc Biol 2007, 27:2435\u20132442.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"37_CR18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2006.09.015","volume":"193","author":"G.D. Norata","year":"2007","unstructured":"Norata GD, Grigore L, Raselli S, et al.: Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193:321\u2013327.","journal-title":"Atherosclerosis"},{"key":"37_CR19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11906-000-0040-0","volume":"2","author":"R.D. Brook","year":"2000","unstructured":"Brook RD: Mechanism of different effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000, 2:370\u2013377.","journal-title":"Curr Hypertens Rep"},{"key":"37_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-122-2-199501150-00010","volume":"122","author":"B.L. Kasiske","year":"1995","unstructured":"Kasiske BL, Ma JZ, Kalil RS, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122:133\u2013141.","journal-title":"Ann Intern Med"},{"key":"37_CR21","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981\u20132997.","journal-title":"JAMA"},{"key":"37_CR22","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.1996.03530440029033","volume":"275","author":"R.H. Grimm","year":"1996","unstructured":"Grimm RH, Flack JM, Grandits GA, et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996, 275:1549\u20131556.","journal-title":"JAMA"},{"key":"37_CR23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archinte.165.8.883","volume":"165","author":"C.A. McMahan","year":"2005","unstructured":"McMahan CA, Gidding SS, Fayad ZA, et al.: Risk scores predict atherosclerotic lesions in young people. Arch Intern Med 2005, 165:883\u2013890.","journal-title":"Arch Intern Med"},{"key":"37_CR24","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2337\/diacare.26.5.1402","volume":"26","author":"G.B. Appel","year":"2003","unstructured":"Appel GB, Radhakrishnan J, Avram MM, et al.: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003, 26:1402\u20131407.","journal-title":"Diabetes Care"},{"key":"37_CR25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-2007-976544","volume":"39","author":"T. Inoue","year":"2007","unstructured":"Inoue T, Morooka T, Moroe K, et al.: Effect of telmisartan on cholesterol levels in patients with hypertension\u2014Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007, 39:372\u2013376.","journal-title":"Horm Metab Res"},{"key":"37_CR26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2337\/dc05-2366","volume":"29","author":"E.N. Taylor","year":"2006","unstructured":"Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065\u20131070.","journal-title":"Diabetes Care"},{"key":"37_CR27","first-page":"137","volume":"18","author":"K.D. Ward","year":"1994","unstructured":"Ward KD, Sparrow D, Vokonas PS, et al.: The relationships of abdominal obesity, hyperinsulinemia and saturated fat intake to serum lipids levels: Normal Aging Study. Int J Obes Relat Metab Disord 1994, 18:137\u2013144.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"37_CR28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM199602083340607","volume":"334","author":"G.M. Reaven","year":"1996","unstructured":"Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374\u2013381.","journal-title":"N Engl J Med"},{"key":"37_CR29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","volume":"37","author":"A.M. Sharma","year":"2001","unstructured":"Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250\u2013254.","journal-title":"Hypertension"},{"key":"37_CR30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00008483-200511000-00008","volume":"25","author":"M. B\u00e9langer","year":"2005","unstructured":"B\u00e9langer M, Boulay P: Effect of an aerobic exercise training program on resting metabolic rate in chronically beta-adrenergic blocked hypertensive patients. J Cardiopulm Rehabil 2005, 25:354\u2013360.","journal-title":"J Cardiopulm Rehabil"},{"key":"37_CR31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1524-6175.2004.03704.x","volume":"6","author":"S. Jacob","year":"2004","unstructured":"Jacob S, Henriksen EJ: Metabolic properties of vasodilating beta-blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2004, 6:690\u2013696.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"37_CR32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/CIRCRESAHA.107.157404","volume":"101","author":"A.T. Remaley","year":"2007","unstructured":"Remaley AT: Old drug, new tricks, the unexpected effect of doxazosin on high-density lipoprotein. Circ Res 2007, 101:116\u2013118.","journal-title":"Circ Res"},{"key":"37_CR33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2337\/diacare.14.3.203","volume":"14","author":"H.O. Lithell","year":"1991","unstructured":"Lithell HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991, 14:203\u2013209.","journal-title":"Diabetes Care"},{"key":"37_CR34","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","volume":"174","author":"N. Khan","year":"2006","unstructured":"Khan N, McAlister FA: Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737\u20131742.","journal-title":"CMAJ"},{"key":"37_CR35","doi-asserted-by":"crossref","unstructured":"Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Am J Cardiol 1985, 55:1\u201315.","DOI":"10.1016\/0002-9149(85)90290-5"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-008-0037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-008-0037-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-008-0037-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:56:19Z","timestamp":1559418979000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-008-0037-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1007\/s11892-008-0037-7","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}